Exploiting somatic alterations as therapeutic targets in advanced and metastatic cervical cancer
- 23 May 2021
- journal article
- review article
- Published by Elsevier in Cancer Treatment Reviews
- Vol. 98, 102225
Abstract
No abstract availableKeywords
Funding Information
- National Cancer Institute (P30 CA008748)
- National Institutes of Health (P30 CA008748)
This publication has 104 references indexed in Scilit:
- Functional Aspects of PARP1 in DNA Repair and TranscriptionBiomolecules, 2012
- Normalization of the Vasculature for Treatment of Cancer and Other DiseasesPhysiological Reviews, 2011
- Phase II study of cisplatin plus cetuximab in advanced, recurrent, and previously treated cancers of the cervix and evaluation of epidermal growth factor receptor immunohistochemical expression: A Gynecologic Oncology Group studyGynecologic Oncology, 2011
- Hallmarks of Cancer: The Next GenerationCell, 2011
- Phase II, Open-Label Study of Pazopanib or Lapatinib Monotherapy Compared With Pazopanib Plus Lapatinib Combination Therapy in Patients With Advanced and Recurrent Cervical CancerJournal of Clinical Oncology, 2010
- The DNA-damage response in human biology and diseaseNature, 2009
- A Phase II Trial of Erlotinib in Recurrent Squamous Cell Carcinoma of the CervixInternational Journal of Gynecological Cancer, 2009
- Transforming growth factor-β in cancer and metastasisCancer and Metastasis Reviews, 2006
- Increased expression of pAKT is associated with radiation resistance in cervical cancerBritish Journal of Cancer, 2006
- Role of the Vascular Endothelial Growth Factor Pathway in Tumor Growth and AngiogenesisJournal of Clinical Oncology, 2005